01501nas a2200265   4500000000100000008004100001653002000042653002200062653001200084653002000096100001300116700001200129700001400141700001200155700001900167700001800186700002200204700001500226700001400241700001600255245012500271300000900396520081600405022001401221       2015                            d10aType 1 reaction10aReversal reaction10aleprosy10aDendritic Cells1 aMoraes M1 aSarno E1 aJardim MR1 aSales A1 aIllarramendi X1 aCosta Nery JA1 aPereira Sampaio E1 aPinheiro R1 aAndrade P1 aBarbosa MGM00aType 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition.  a1-173 a<p>Type 1 reaction (T1R) or reversal reaction is the leading cause of physical disabilities and deformities in leprosy. Leprosy patients, even after being considered cured and released from treatment, may suffer from reactional episodes for long periods of time. Early diagnosis is a great challenge for effectively treating and managing T1R. There is an urgent need to identify the most significant biomarkers to prevent recurrent T1R and to differentiate late T1R from relapse. T1R continues to be treated with corticosteroids and complications due to iatrogenic treatment remain frequent. This review aims to provide a framework from which to approach the great challenges that still persist in T1R management and debate key issues in order to reduce the distance between basic research and the clinic.</p>
  a1744-8409